Terns Pharmaceuticals (NASDAQ:TERN) Stock Rating Lowered by Wall Street Zen

Terns Pharmaceuticals (NASDAQ:TERN) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

TERN has been the subject of a number of other research reports. Barclays lifted their target price on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Citizens Jmp raised their price target on Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a research note on Thursday, December 11th. JMP Securities set a $35.00 price objective on Terns Pharmaceuticals in a research report on Wednesday, November 26th. Citigroup reissued an “outperform” rating on shares of Terns Pharmaceuticals in a report on Wednesday, November 26th. Finally, Jefferies Financial Group restated a “buy” rating and set a $70.00 price target on shares of Terns Pharmaceuticals in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.56.

Terns Pharmaceuticals Price Performance

Terns Pharmaceuticals stock opened at $36.60 on Friday. Terns Pharmaceuticals has a one year low of $1.87 and a one year high of $48.26. The business’s fifty day moving average is $34.51 and its 200 day moving average is $16.98. The stock has a market capitalization of $3.30 billion, a PE ratio of -35.53 and a beta of -0.28.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.03. As a group, sell-side analysts expect that Terns Pharmaceuticals will post -1.19 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the transaction, the insider owned 50,365 shares of the company’s stock, valued at $1,942,578.05. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jill M. Quigley sold 24,520 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $18.00, for a total value of $441,360.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 165,763 shares of company stock worth $5,752,450 over the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals during the 3rd quarter valued at $42,807,000. Vanguard Group Inc. raised its holdings in Terns Pharmaceuticals by 5.9% during the third quarter. Vanguard Group Inc. now owns 4,559,917 shares of the company’s stock valued at $34,245,000 after acquiring an additional 253,751 shares during the period. Candriam S.C.A. raised its holdings in Terns Pharmaceuticals by 9.9% during the second quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock valued at $8,834,000 after acquiring an additional 214,266 shares during the period. Geode Capital Management LLC lifted its position in shares of Terns Pharmaceuticals by 3.8% in the second quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock valued at $6,094,000 after acquiring an additional 59,145 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of Terns Pharmaceuticals in the second quarter worth about $4,774,000. 98.26% of the stock is owned by hedge funds and other institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.